You just read:

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis

News provided by

Eli Lilly and Company

Jun 01, 2018, 12:04 ET